Sales of Smore International Down 18.7% in H1 2022

Aug.24.2022
Simaol International reports a 18.7% decrease in sales and 51.7% decrease in net profit in H1 2022 due to various factors.

On August 24th, Somor International disclosed that in the first half of 2022, the group's sales revenue reached RMB 5.653 billion during the review period, a decrease of 18.7% compared to the same period last year. During this period, the net profit fell to RMB 1.385 billion, and the overall revenue decreased to RMB 1.384 billion. Adjusted net profit for the review period was RMB 1.436 billion, a decrease of 51.7% compared to the same period last year. The main reasons for the group's decline in net profit during the review period were lower sales from enterprise customers, declining gross profit margins, and increased sales, management, and research and development expenses.


Sales revenue for enterprise customers decreased by 21.6% compared to the same period last year, accounting for a percentage drop from 93.4% to 90.1% of total revenue; while sales revenue for retail customers increased by 22.9% compared to the same period last year, accounting for a percentage increase from 6.6% to 9.9% of total revenue.


There has been a short-term decrease in sales in the US market. Products transported through Hong Kong resulted in a 33.0% decrease in sales revenue to enterprise customers in the US market compared to the same period last year. The percentage of total revenue also decreased from 34.6% to 28.6% during the same period.


During the review period, the group experienced a decrease in sales in the Chinese market compared to the high base in the first half of 2021. Excluding export sales to Chinese traders, the group's sales revenue to enterprise customers in China decreased by 40.1% compared to the same period last year. The proportion of this revenue to the total revenue decreased from 40.8% in the same period last year to 30.0% in the review period.


This article contains excerpts or reproductions of content from third-party sources. The copyright of this content belongs to the original media and author. If there is any infringement, please contact us to delete it. Any individual or organization wishing to repost this content should contact the author and refrain from reposting it directly.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

ACT Health Minister Vows Continued Crackdown on E-Cigarettes and Illicit Tobacco
ACT Health Minister Vows Continued Crackdown on E-Cigarettes and Illicit Tobacco
ACT Health Minister Rachel Stephen-Smith said the government would not ease its action against e-cigarettes and illicit tobacco and would continue strengthening regulation, legislation, and enforcement. Speaking at the launch of a new program to help young people quit vaping, she said reducing tobacco excise would not materially reduce profits in the illicit tobacco market.
Mar.10 by 2FIRSTS.ai
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11
Thai Customs Plans Shift to Per-Unit Fines for Vapes at THB 100 Per Item
Thai Customs Plans Shift to Per-Unit Fines for Vapes at THB 100 Per Item
Thai Customs said on March 18 that it had seized more than 27.3 million foreign cigarettes and 205,445 vape products and related devices in mid-February, with a total value of more than THB 169 million.
Mar.19 by 2FIRSTS.ai
STG UK refreshes XQS nicotine pouch packaging: new flavour indicators, hitting retail from March
STG UK refreshes XQS nicotine pouch packaging: new flavour indicators, hitting retail from March
Scandinavian Tobacco Group UK (STG UK) has announced a rebrand across its XQS nicotine pouch range. The updated packaging will be visible at retail from March, with the recommended retail price remaining £5.50. The new packs feature a bolder logo and glossy textures, retain nicotine strength indicators, and add a side flavour profile indicator to show the flavour type.
Feb.28 by 2FIRSTS.ai
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.
Feb.11
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11